Selected publications
*indicates equal contribution and # indicates corresponding authorship.
Vasudev NS*, Scelo G*, Glennon KI*, Wilson M, Letourneau L, Eveleigh R, Nourbehesht N, Arseneault M, Paccard A, Egevad L, Viksna J, Celms E, Jackson SM, Abedi-Ardekani B, Warren AY, Selby PJ, Trainor S, Kimuli M, Cartledge J, Soomro N, Adeyoju A, Patel PM, Wozniak MB, Holcatova I, Brisuda A, Janout V, Chanudet E, Zaridze D, Moukeria A, Shangina O, Foretova L, Navratilova M, Mates D, Jinga V, Bogdanovic L, Kovacevic B, Cambon-Thomsen A, Bourque G, Brazma A, Tost J, Brennan P, Lathrop M, Riazalhosseini Y#, Banks RE#. Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma. Clinical Cancer Research. 2023 Apr 3;29(7):1220-1231. doi: 10.1158/1078-0432.CCR-22-1936.
Perron G, Jandaghi P, Moslemi E, Nishimura T, Rajaee M, Alkallas R, Lu T, Riazalhosseini Y, Najafabadi HS (2022): Pan-cancer analysis of mRNA stability for decoding tumour post-transcriptional programs. Communications Biology 5, 851. doi:10.1038/s42003-022-03796-w.
Yang H, Messina-Pacheco J, Corredor ALG, Gregorieff A, Liu JL, Nehme A, Najafabadi HS, Riazalhosseini Y, Gao B, Gao ZH (2022): An integrated model of acinar to ductal metaplasia-related N7-methyladenosine regulators predicts prognosis and immunotherapy in pancreatic carcinoma based on digital spatial profiling. Frontiers Immunology 13. doi: 10.3389/fimmu.2022.961457.
Daniel P, Meehan B, Sabri S, Jamali F, Sarkaria JN, Choi D, Garnier D, Kitange G, Glennon KI, Paccard A, Karamchandani J, Riazalhosseini Y, Rak J, Abdulkarim B (2022): Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. Neurooncology Advances 4(1). doi: 10.1093/noajnl/vdac076.
McIntyre WB, Karimzadeh M, Riazalhosseini Y, Khazaei M, Fehlings MG (2022): Cell-Cell Contact Mediates Gene Expression and Fate Choice of Human Neural Stem/Progenitor Cells. Cells 11(11):1741. doi: 10.3390/cells11111741.
Assidicky R, Tokat UM, Tarman IO, Saatci O, Ersan PG, Raza U, Ogul H, Riazalhosseini Y, Can T, Sahin O (2022): Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. Breast Cancer Research and Treatment 193:331-348. doi: 10.1007/s10549-022-06569-5.
Glennon KI, Maralani M, Abdian N, Paccard A, Montermini L, Nam AJ, Arseneault M, Staffa A, Jandaghi P, Meehan B, Brimo F, Tanguay S, Rak J, Riazalhosseini Y# (2021): Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma. Cancers 13(22):5825. doi: 10.3390/cancers13225825.
Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin Ö, Sato H, Schlam I, Sørlie T, Stover DG, Swain SM, Swarbrick A, Thompson EA, Tolaney SM, Warren SE, On Behalf Of The GeoMx Breast Cancer Consortium (2021): Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler. Cancers 13(17):4456. doi: 10.3390/cancers13174456.
Willis-Owen SAG, Domingo-Sabugo C, Starren E, Liang L, Freidin MB, Arseneault M, Zhang Y, Lu SK, Popat S, Lim E, Nicholson AG, Riazalhosseini Y, Lathrop M, Cookson WOC, Moffatt MF (2021): Y disruption, autosomal hypomethylation and poor male lung cancer survival. Scientific Reports 11(1):12453. doi: 10.1038/s41598-021-91907-8.
Khalesi R, Razmara E, Asgaritarghi G, Tavasoli AR, Riazalhosseini Y, Auld D, Garshasbi M (2021): Novel manifestations of Warburg micro syndrome type 1 caused by a new splicing variant of RAB3GAP1: a case report. BMC Neurology 21(1):180. doi: 10.1186/s12883-021-02204-w.
Tawil N, Bassawon R, Meehan B, Nehme A, Montermini L, Gayden T, De Jay N, Spinelli C, Chennakrishnaiah S, Choi D, Adnani L, Zeinieh M, Jabado N, Kleinman CL, Witcher M, Riazalhosseini Y, Key NS, Schiff D, Grover SP, Mackman N, Couturier CP, Petrecca K, Suvà ML, Patel A, Tirosh I, Najafabadi H, Rak J (2021): Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Advances 5(6):1682-1694. doi: 10.1182/bloodadvances.2020002998.
Abedi-Ardekani B, Nasrollahzadeh D, Egevad L, Banks RE, Vasudev N, Holcatova I, Povysil C, Foretova L, Janout V, Mates D, Jinga V, Petrescu A, Milosavljevic S, Ognjanovic M, Ognjanovic S, Viksna J, Warren AY, Lathrop M, Riazalhosseini Y, Carreira C, Chanudet E, McKay J, Brennan P, Scélo G (2021): Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer. Virchows Archiv 478(6):1099-1107. doi: 10.1007/s00428-020-02986-3.
Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N; PCAWG Tumour Subtypes and Clinical Translation, Boutros PC; PCAWG Consortium (2020): Sex differences in oncogenic mutational processes. Nature Communications 11(1):4330. doi: 10.1038/s41467-020-17359-2.
Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Kelso S; MC3 Working Group; PCAWG novel somatic mutation calling methods working group, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L; PCAWG Consortium (2020): Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications 11(1):4748. doi: 10.1038/s41467-020-18151-y.
Wang Y, Park JYP, Pacis A, Denroche RE, Jang GH, Zhang A, Cuggia A, Domecq C, Monlong J, Raitses-Gurevich M, Grant RC, Borgida A, Holter S, Stossel C, Bu S, Lungu I, Bartlett J, Wilson JM, Gao ZH, Riazalhosseini Y, Asselah J, Bouganim N, Cabrera T, Boucher LM, Valenti D, Biagi J, Greenwood CMT, Polak P, Foulkes WD, Golan T, O’Kane GM, Fischer SE, Knox JJ, Gallinger S, Zogopoulos G (2020): A preclinical trial and molecularly-annotated patient cohort identify therapeutic and prognostic biomarkers in homologous recombination deficient pancreatic cancer. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-20-1439.
Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, Sikirzhytski V, Tokat UM, Aykut G, Ansari SA, Dogan HT, Dogan M, Jandaghi P, Isik A, Gundogdu F, Kosemehmetoglu K, Dizdar O, Aksoy S, Akyol A, Uner A, Buckhaults PJ, Riazalhosseini Y, Sahin O (2020): Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature Communications 11(1):2416.
Hornigold N*, Dunn KR*, Craven RA*, Zougman A, Trainor S, Shreeve R, Brown J, Sewell H, Shires M, Knowles M, Fukuwatari T, Maher ER, Harris A, Burns J, Bhattarai S, Menon M, Brazma A, Scelo G, Feulner L, Riazalhosseini Y, Lathrop M, Selby PJ, Banks RE, Vasudev NS (2020): Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumor immune evasion. British Journal of Cancer 123(1):137-147.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2020). Nature. Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6.
Nikbakht H, Jessa S, Sukhai MA, Arseneault M, Zhang T, Letourneau L, Thomas M, Bourgey M, Roehrl MHA, Eveleigh R, Chen EX, Krzyzanowska M, Moore MJ, Giesler A, Yu C, Bedard PL, Kamel-Reid S, Majewski J, Siu LL, Riazalhosseini Y#, Graham DM# (2020): Dormancy and interval therapy affect the evolution in metastatic colorectal cancer. Scientific Reports 10(1):581. doi: 10.1038/s41598-020-57476-y.
Mehvari S, Larti F, Hu H, Fattahi Z, Beheshtian M, Abedini, SS. Arzhangi S, Ropers HH, Kalscheuer VM, Auld D, Kahrizi K, Riazalhosseini Y#, Najmabadi H# (2020): Whole genome sequencing identified a duplicated region encompassing Xq13.2-q13.3 in a large Iranian family with intellectual disability. Molecular Genetics and Genomic Medicine e1418. doi: 10.1002/mgg3.1418.
Imai-Okazaki A, Li Y, Horpaopan S, Riazalhosseini Y, Garshasbi M, Mosse YP, Zhang D, Schrauwen I, Sharma A, Fann CSJ, Leal SM, Lathrop M, Ott J# (2019): Heterozygosity mapping for human dominant trait variants. Human Mutation. 40(7):996-1004.
Bakadlag R, Jandaghi P, Hoheisel JD, Riazalhosseini Y# (2019): The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer. Expert Opinion on Therapeutic Targets 23(5):365-367.
Feulner L, Najafabadi HS, Tanguay S, Rak J#, Riazalhosseini Y# (2019): Age-related variations in gene expression patterns of renal cell carcinoma. Urologic Oncology 37(2):166-175.
Karimzadeh M, Jandaghi P, Papadakis Al, Trainor S, Rung J, Gonzàkez-Porta M, Scelo G, Vasudev NS, Brazma A, Huang S, Banks RE, Lathrop M, Najafabadi HS, Riazalhosseini Y# (2018): Aberration hubs in protein interaction networks highlight actionable targets in cancer. Oncotarget 9:25166-80.
Perron G*, Jandaghi P*, Solanki S, Safisamghabadi M, Storoz C, Karimzadeh M, Papadakis Al, Arseneault M, Scelo G, Banks RE, Tost J, Lathrop M, Tanguay S, Brazma A, Huang S, Brimo F, Najafabadi HS, Riazalhosseini Y# (2018): A General Framework for Interrogation of mRNA Stability Programs Identifies RNA-Binding Proteins that Govern Cancer Transcriptomes. Cell Reports 23(6): 1639-50.
Robinson CM, Lefebvre F, Poon BP, Bousard A, Fax X, Lathrop M, Tost J, Kim WY, Riazalhosseini Y, Ohh M (2018): Consequences of VHL Loss on global DNA Methylome. Scientific Reports 8(1):3313.
Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, Ersan PG, Tokat UM, Eyupoglu E, Saatci O, Jandaghi P, Wiemann S, Under A, Cekic C, Riazalhosseini Y, Sahin O (2018): Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. Clinical Cancer Research 24(8):1987-2001.
Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hebert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA (2018): The genomic landscape of two Burkitt lymphoma cases and derived cell lines: a comparison between primary and relapse samples. Leukemia & Lymphoma, doi: 10.1080/10428194.2017.1413186.
Mehdi A, Riazalhosseini Y# (2017): Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences 18(8):1774.
Arseneault M*, Monlong J*, Vasudev NS, Laskar RS, Safisamghabadi M, Harnden P, Egevad L, Nourbehesht N, Panichnantakul P, Holcatova I, Brisuda A, Janout V, Kollarova H, Foretova L, Navratilova M, Mates D, Kinga V, Zaridze D, Mukeria A, Jandaghi P, Brennan P, Brazma A, Tost J, Scelo G, Banks RE, Lathrop M, Bourque G, Riazalhosseini Y# (2017): Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma. Scientific Reports, doi: 10.1038/srep44876.
Yasser Riazalhosseini# and Mark Lathrop# (2016): Precision medicine from the renal cancer genome. Nature Reviews Nephrology 12(11): 655-666 [Featured Article].
Pudchalaluck Panichnantakul, Mathieu Bourgey, Alexandre Montpetit, Guillaume Bourque, Yasser Riazalhosseini# (2016): RNA-seq as a tool to study the tumor microenvironment. Methods in Molecular Biology 1458:311-37.
Pouria Jandaghi, Hamed S. Najafabadi, Andrea S. Bauer, Andreas I. Papadakis, Matteo Fassan, Anita Hall, Anie Monast, Magnus von Knebel Doeberitz, John P. Neoptolemos, Eithne Costello, William Greenhalf, Aldo Scarpa, Bence Sipos, Daniel Auld, Mark Lathrop, Morag Park, Markus W. Büchler, Oliver Strobel, Thilo Hackert, Nathalia A. Giese, George Zogopoulos, Veena Sangwan, Sidong Huang, Yasser Riazalhosseini#, Jörg D. Hoheisel (2016): Expression of DRD2 is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Gastroenterology, doi: 10.1053/j.gastro.2016.08.040.
